<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
      version="3.7"
      xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-7.xsd">
   <titleInfo>
      <title>4-HIL mitigates type-2 diabetic complications through inhibiting inflammation and Nrf2 mediated oxidative stress in rats</title>
   </titleInfo>
   <name type="personal" usage="primary">
      <namePart type="given">Rupali</namePart>
      <namePart type="family">Singh</namePart>
      <displayForm>Singh, Rupali</displayForm>
      <affiliation>Division of Toxicology and Experimental Medicine</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Karan Singh</namePart>
      <namePart type="family">Yadav</namePart>
      <displayForm>Yadav, Karan Singh</displayForm>
      <affiliation>Division of Toxicology and Experimental Medicine</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Ramanand</namePart>
      <namePart type="family">Prajapati</namePart>
      <displayForm>Prajapati, Ramanand</displayForm>
      <affiliation>Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow, India, 226 031</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Sharad</namePart>
      <namePart type="family">Sharma</namePart>
      <displayForm>Sharma, Sharad</displayForm>
      <affiliation>Division of Toxicology and Experimental Medicine</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Srikanta Kumar</namePart>
      <namePart type="family">Rath</namePart>
      <displayForm>Rath, Srikanta Kumar</displayForm>
      <affiliation>Division of Toxicology and Experimental Medicine</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Tadigoppula</namePart>
      <namePart type="family">Narender</namePart>
      <displayForm>Narender, Tadigoppula</displayForm>
      <affiliation>Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow, India, 226 031</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <name type="personal">
      <namePart type="given">Madhav Nilakanth</namePart>
      <namePart type="family">Mugale</namePart>
      <displayForm>Mugale, Madhav Nilakanth</displayForm>
      <affiliation>Division of Toxicology and Experimental Medicine</affiliation>
      <role>
         <roleTerm type="text">author</roleTerm>
      </role>
   </name>
   <typeOfResource>text</typeOfResource>
   <genre>article</genre>
   <originInfo>
      <dateIssued encoding="w3cdtf" keyDate="yes">2022-02</dateIssued>
   </originInfo>
   <language>
      <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
      <languageTerm type="text">English</languageTerm>
   </language>
   <abstract>Hyperglycemia induced diabetic complications as well as dysfunction of multiple organs is closely related to the increased inflammation and oxidative stress (OS). 4-hydroxyisoleucine (4-HIL), a major constituent of Trigonella foenum-graecum L. shown to have anti-diabetic effects. However, its potential mechanism against diabetic complications in the model of metabolic syndrome have not yet been characterized. The present study aimed to investigate the ameliorative effects of 4-HIL in rat model of metabolic syndrome and to explore the possible mechanism of action. Male Sprague dawley rat of 6 -7 weeks were administrated with 4-HIL by oral gavage from 12 to 20 weeks after development of complications. At the end of the study, all animals were sacrificed. Tissues and blood samples were collected for histopathologic and biochemical analysis. Serum metabolic parameters, level of triglycerides, glycated hemoglobin, activities of antioxidant enzymes were estimated. Pathological changes in the tissues were assessed by Hematoxylin – Eosin (H &amp; E), Masson's trichrome and Periodic Acid - Schiff (PAS) staining. In vivo gene expressions were demonstrated by Western blotting. Oral administration of 4-HIL (200 mg kg−1) reduced the body hyperglycemia, glycated hemoglobin (HbA1c), creatinine, blood urea nitrogen (BUN), triglyceride and restored the histopathological indices when compared with the diabetic control group. The 4-HIL increased the activities of antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT) and glutathione (GSH) in tissues samples. It down-regulate the expression of vascular endothelial growth factor (VEGF), tissue injury molecule-1 (TIM-1), insulin receptor (INSULIN R) and transforming growth factor beta 1 (TGF-β1) mediated inflammatory response in all the tissues. Moreover, it exhibits protective effect against oxidative stress by activation of nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway-related proteins in the tissues. The findings highlight the beneficial role of 4-HIL in diabetic complications by decreasing inflammatory response and oxidative stress through TGF-β1 signaling pathway and activation of Nrf2 gene expression respectively in addition to its effect on glycemic control. </abstract>
   <subject>
      <topic>4-hydroxyisoleucine</topic>
   </subject>
   <subject>
      <topic>Antioxidant</topic>
   </subject>
   <subject>
      <topic>Diabetic complication</topic>
   </subject>
   <subject>
      <topic>Inflammation</topic>
   </subject>
   <subject>
      <topic>Oxidative stress</topic>
   </subject>
   <subject>
      <topic>T2DM</topic>
   </subject>
   <subject>
      <topic>4-HIL</topic>
   </subject>
   <subject>
      <topic>STZ</topic>
   </subject>
   <subject>
      <topic>DN</topic>
   </subject>
   <subject>
      <topic>DR</topic>
   </subject>
   <subject>
      <topic>ROS/RNS</topic>
   </subject>
   <subject>
      <topic>INSULIN R</topic>
   </subject>
   <subject>
      <topic>VEGF</topic>
   </subject>
   <subject>
      <topic>TIM-1</topic>
   </subject>
   <subject>
      <topic>TGF-β1</topic>
   </subject>
   <subject>
      <topic>Nrf2</topic>
   </subject>
   <subject>
      <topic>BUN</topic>
   </subject>
   <subject>
      <topic>HbA1c</topic>
   </subject>
   <subject>
      <topic>SGPT</topic>
   </subject>
   <subject>
      <topic>PAS</topic>
   </subject>
   <subject>
      <topic>LDL</topic>
   </subject>
   <subject>
      <topic>HDL</topic>
   </subject>
   <subject>
      <topic>AGEs</topic>
   </subject>
   <subject>
      <topic>ALT</topic>
   </subject>
   <subject>
      <topic>CAT</topic>
   </subject>
   <subject>
      <topic>GSH</topic>
   </subject>
   <subject>
      <topic>H &amp; E</topic>
   </subject>
   <relatedItem type="host">
      <titleInfo>
         <title>Phytomedicine Plus</title>
      </titleInfo>
      <originInfo>
         <publisher>Elsevier B.V.</publisher>
      </originInfo>
      <identifier type="issn">2667-0313</identifier>
      <part>
         <detail type="volume">
            <number>2</number>
            <caption>v.</caption>
         </detail>
         <detail type="issue">
            <number>1</number>
            <caption>no.</caption>
         </detail>
         <text type="display-date">February 2022</text>
         <text type="year">2022</text>
         <text type="month">February</text>
         <extent unit="pages">
            <start>100141</start>
         </extent>
      </part>
   </relatedItem>
   <identifier type="doi">10.1016/j.phyplu.2021.100141</identifier>
   <location>
      <url>http://dx.doi.org/10.1016/j.phyplu.2021.100141</url>
   </location>
   <identifier type="pii">S2667-0313(21)00123-8</identifier>
   <accessCondition type="use and reproduction"
                    displayLabel="Creative Commons Attribution 4.0 Generic (CC BY 4.0)">
      <program xmlns="https://data.crossref.org/schemas/AccessIndicators.xsd">
         <licence_ref applies_to="reuse" start_date="2021-10-21"/>
         <licence_ref>http://creativecommons.org/licenses/by/4.0/</licence_ref>
      </program>
   </accessCondition>
   <extension>
      <vendorName/>
      <archiveFile/>
      <originalFile>file:/C:/Users/Carlos.Martinez/OneDrive%20-%20USDA/XML_projects/OpenAccess/OpenAccess/transform/source/sourcefiles/576450669703096969-00001/2667-0313/S2667031321X00061/S2667031321001238/S2667031321001238.xml</originalFile>
      <workingDirectory>C:\Users\Carlos.Martinez\OneDrive - USDA\XML_projects\OpenAccess\OpenAccess\transform\result\</workingDirectory>
   </extension>
</mods>
